Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Isatuximab, Bortezomib, and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the blood. The study is testing a combination of treatments to see how effective they are in treating this condition. The treatments being used in the study include Isatuximab, which is a humanized monoclonal antibody that targets a protein called CD38, Lenalidomide, Dexamethasone, and Bortezomib. Isatuximab is also known by its code name, SAR650984. These medications are used together to see if they can help patients achieve a state called minimal residual disease (MRD) negativity, which means that there are no detectable cancer cells left in the body after treatment.

The purpose of the study is to determine how many patients achieve MRD negativity during or after receiving the combination of these treatments. The study will involve several cycles of treatment, starting with two cycles of a combination called IVRd, which includes Isatuximab, Bortezomib, Lenalidomide, and a minimal amount of Dexamethasone. This is followed by six cycles of IVR, which includes Isatuximab, Bortezomib, and Lenalidomide, and then ten cycles of IR, which includes Isatuximab and Lenalidomide. The study is designed to be open-label, meaning that both the researchers and the participants know which treatments are being administered.

Participants in the study will receive these treatments over a period of time, with the maximum treatment period being 18 cycles. The study aims to assess the effectiveness of the treatment combination in achieving MRD negativity and to monitor the overall health and quality of life of the participants. The study will also track any side effects or adverse events that occur during the treatment period. This research is important for understanding how well these treatments work together in patients with newly diagnosed multiple myeloma who are not eligible for a type of transplant called autologous transplant.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and consent

    Upon joining the study, the first step involves an initial visit where the study details are explained. A written informed consent is required to confirm understanding and willingness to participate.

    During this visit, eligibility is confirmed based on specific criteria, including age, diagnosis of multiple myeloma, and overall health status.

  2. Step 2

    Screening phase

    A series of tests are conducted to ensure eligibility. These tests include blood tests to check bone marrow and kidney function, and a pregnancy test for females of childbearing potential.

    The screening phase ensures that all health parameters meet the study requirements before starting the treatment.

  3. Step 3

    Treatment cycle 1 and 2 (IVRd)

    The treatment begins with two cycles of a combination therapy called IVRd, which includes isatuximab administered intravenously, lenalidomide taken orally, dexamethasone taken orally, and bortezomib given as a subcutaneous injection.

    Each cycle lasts for a specific period, and the medications are given at prescribed dosages and frequencies as determined by the study protocol.

  4. Step 4

    Treatment cycle 3 to 8 (IVR)

    Following the initial two cycles, the treatment continues with six cycles of IVR, which includes isatuximab, lenalidomide, and bortezomib.

    The frequency and dosage of each medication are adjusted according to the study protocol, and regular monitoring is conducted to assess response and manage any side effects.

  5. Step 5

    Treatment cycle 9 to 18 (IR)

    The final phase of treatment consists of ten cycles of IR, involving isatuximab and lenalidomide.

    Throughout these cycles, the patient's health and response to treatment are closely monitored, with adjustments made as necessary to ensure safety and effectiveness.

  6. Step 6

    Regular monitoring and assessments

    During the entire study period, regular visits are scheduled to monitor health status, treatment response, and any side effects.

    These assessments include blood tests, physical examinations, and other necessary evaluations to ensure the treatment is working as intended.

  7. Step 7

    End of study

    Upon completion of the treatment cycles, a final assessment is conducted to evaluate the overall response to the treatment.

    The study aims to determine the proportion of patients achieving minimal residual disease negativity, which indicates a significant reduction in cancer cells.

Who can join the trial?

10 criteria

  • Voluntary written informed consent is required.
  • Participant must be over 18 years of age at the time of signing the informed consent.
  • Must have newly diagnosed multiple myeloma and not be eligible for high-dose therapy and ASCT (a type of stem cell transplant).
  • Must have measurable disease as defined by the International Myeloma Working Group, which includes specific levels of M-protein in the blood or urine, or specific levels of immunoglobulin in the blood.
  • Must have an ECOG performance status score of 0, 1, or 2. A score of 3 is allowed only if it is caused by myeloma. (ECOG performance status is a scale used to assess how a disease affects a patient's daily living abilities.)
  • Must have certain clinical laboratory values during the screening phase, including:
    • Adequate bone marrow function, such as hemoglobin levels above 7.5 g/dL, absolute neutrophil count above 1.0 x 109/L, and platelet count above 70 x 109/L.
    • Adequate kidney function, with an eGFR (a test to measure kidney function) above 30 mL/min/m2.
    • Patient must be willing and able to follow the study protocol visit schedule and other requirements.
    • Females of childbearing potential must have a confirmed negative pregnancy test within 10-14 days before and again within 24 hours before starting study medication.
    • Females of childbearing potential and male participants who are sexually active with females of childbearing potential must agree to use highly effective birth control methods during the study and for at least 5 months after the last dose of isatuximab treatment and at least 28 days after the last lenalidomide treatment. Male participants must also refrain from donating sperm during this period.

Who cannot join the trial?

3 criteria

  • Patients who do not have a diagnosis of multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow.
  • Patients who are not within the specified age range cannot participate. The age range for this study is not specified in the provided data.
  • Patients who are part of a vulnerable population cannot participate. Vulnerable populations may include groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Isatuximab

    is a type of medication known as a monoclonal antibody. It works by targeting a specific protein on the surface of cancer cells, which helps the immune system to recognize and destroy these cells. In this trial, isatuximab is used to help treat multiple myeloma, a type of blood cancer, by reducing the number of cancer cells in the body.

  • Bortezomib

    is a medication that helps to treat multiple myeloma by interfering with the growth of cancer cells. It works by blocking a certain protein that cancer cells need to grow and multiply. This helps to slow down or stop the progression of the disease.

  • Lenalidomide

    is a medication that helps to treat multiple myeloma by affecting the immune system. It works by enhancing the body's immune response to fight cancer cells and also by directly attacking the cancer cells to prevent them from growing and spreading.

  • Dexamethasone

    is a type of steroid medication that is used to reduce inflammation and suppress the immune system. In the context of this trial, it is used in small amounts to help enhance the effects of the other medications and to manage side effects associated with the treatment of multiple myeloma.

What is already known about the treatment

Isatuximab – Isatuximab is administered through an intravenous infusion, meaning it is given directly into the bloodstream via a vein. It is currently being studied in clinical trials for its effectiveness in treating multiple myeloma, a type of blood cancer. The main therapeutic use of isatuximab is to help eliminate cancer cells in patients with multiple myeloma who are not eligible for a stem cell transplant. At the molecular level, isatuximab works by targeting a specific protein on the surface of cancer cells, helping the immune system to recognize and destroy these cells. It is classified as a monoclonal antibody, which is a type of medication designed to target specific proteins in the body.

Investigated diseases

Multiple myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and crowd out healthy blood cells, leading to bone damage, anemia, and increased risk of infections. As the disease progresses, it can cause bone pain, fractures, and kidney problems due to the accumulation of abnormal proteins produced by the cancerous cells. Over time, the disease can lead to significant bone loss and damage to other organs. The progression of multiple myeloma is often characterized by periods of remission and relapse. It is a chronic condition that requires ongoing monitoring and management.
Trial detailsLast updated 7 Oct 2026
Age65+ yearsPhasePhase IITrial ID2023-510194-34-00Estimated enrolment51 patientsSponsorOslo University Hospital HF

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.